Sustained virologic response improved the long-term health-related quality of life in patients with chronic hepatitis C: a prospective national study in China.

Background

It was estimated that 57.8 million (0·8%) people were living with chronic hepatitis C virus (HCV) infection worldwide [ 1 ]. Hepatitis C is responsible for an estimated 399,000 deaths each year, primarily from cirrhosis and hepatocellular carcinoma (HCC) [ 2 ]. The disease burden of HCV infection is significant, as it can cause chronic liver disease that can progress over time, leading to significant morbidity, mortality, and healthcare costs. The key milestone in the therapy of hepatitis C was direct-acting antivirals (DAAs) in the 2010s, with rates of sustained virologic response (SVR) above 95% and are generally well-tolerated [ 3 , 4 ]. Although the global burden of HCV has been on the decline, the impact of hepatitis C in terms of disease burden remains substantial, as evidenced by disability-adjusted life years (DALYs) of 146.2 attributed to HCV-related cirrhosis and 34.9 attributed to HCV-related HCC in the year 2019 [ 5 , 6 ].

Severe impairment of patient-reported outcomes (PROs) in patients with chronic HCV infection was seen in real-world practices across the world, while fatigue and psychiatric comorbidities were associated with significant PROs impairment in chronic hepatitis C (CHC) patients [ 7 ]. Besides, our previous study indicated health-related quality of life (HRQoL) of Chinese CHC patients was also impaired and associated with symptoms of discomfort, cirrhosis and depression [ 8 ]. Some studies suggested that utilities improved after DAAs treatment in patients with CHC [ 9 , 10 ].

Although there are some relevant studies [ 11 , 12 ], there is currently a lack of prospective longitudinal studies in the real world on HRQoL of hepatitis C patients who have achieved SVR. It is not yet clear which factors will continue to impact the quality of life of HCV patients after virus elimination. Expecting to provide some new evidence for the medical care of HCV patients after SVR, we conducted this prospective longitudinal multicenter study across China to understand the trends of change in HRQoL of Chinese HCV patients after SVR in the real world and the impact of antiviral therapy on them.

Methods

This study aimed to assess longitudinal impact of antiviral treatment and SVR on HRQoL of patients with CHC, and to identify significant predictors of the HRQoL in these patients.

Study design and patients

This study is a component of the prospective observational study, CCgenos (ClinicalTrials.gov identifier NCT01594554 ; BMS study ID AI452-018ST, Registration date: 09/05/2012), which was conducted at 28 university hospitals across China. The cross-sectional phase of the CCgenos study included Han Chinese adults who had recently been diagnosed with chronic HCV infection, characterized by a positive anti-HCV antibody and HCV-RNA test, and who had not undergone prior interferon-based treatment for HCV or hepatitis B virus [ 13 ]. Following the cross-sectional study, patients were invited to participate in a 5-year follow-up starting in 2012. Patients who did not provide consent to be followed up, patients for whom the data did not qualify for analysis due to major protocol deviation(s) and patients were formally enrolled into any investigational drug clinical trial after the cross-sectional phase of the CCgenos study were excluded. Patients without complete data about HRQoL were also excluded. No other exclusion criteria were applied for the follow-up phase, and no randomization or protocol-driven treatment was implemented [ 14 ]. The study protocols were approved by a central review board (the ethics committee of Peking University People’ s Hospital), the institutional review boards of each participating center, and the China National Human Genetic Resource Management Office (2010). The study adhered to the International Society for Pharmacoepidemiology guidelines for Good Epidemiology Practices and applicable regulatory requirements. All patients provided written informed consent before participating in the study.

Sociodemographic and clinical characteristics

At enrollment, we collected sociodemographic characteristics such as gender, age, place of residence, marital status, occupation, level of education, and economic status. Residence was recorded according to patients’ current locations, including east, west, south, north and central. The division of China into its eastern, southern, western, northern, and central regions is based on geographical directions. Occupation includes white collar (cadre, health care, teacher and self-employed), blue collar (laborer, farming, service and athlete), unemployed and other (student and others). We also considered various clinical characteristics, including discomfort symptoms such as moderate or severe malaise, decreased appetite, nausea, discomfort in the right hypochondrium, fever, xanthochromia, xanthurenic acid, and other uncomfortable symptoms. Due to the diverse extrahepatic manifestations of CHC, and considering the previous literature reporting that these manifestations might affect the HRQoL [ 15 ], we examined extrahepatic manifestations, such as Behcet’s disease, cryoglobulinemia, prediabetes, diabetes, hyperlipidemia, fatty liver, insulin resistance, fibromyalgia, membranoproliferative glomerulonephritis, membranous nephropathy, multiple myeloma, Raynaud’s syndrome, rheumatoid arthritis, Sjögren syndrome, systemic lupus erythematosus, thyroid dysfunction, skin lesions, hypertrophic cardiomyopathy, porphyria cutanea tarda, lichen planus, vasculitis, and pulmonary fibrosis. A detailed table that includes diagnosis, symptoms, sign, lab test and pathology of individual extrahepatic manifestation of CHC was constructed to collect the information above.

Cirrhosis was diagnosed using several criteria, including liver biopsy or the presence of ascites, hepatic encephalopathy, upper gastrointestinal bleeding, or Child-Turcotte-Pugh score > 7, or by any two of the following criteria: radiologic imaging showing nodular liver or splenomegaly, platelet count < 100 × 10 9 /L in the absence of other explanations, liver stiffness > 13kPA, or endoscopic detection of gastroesophageal varices. We also calculated Beck’s depression score, which indicates clinical depression with a score of ≥ 17.

We collected clinical information and performed centralized HCV RNA testing every 6 ± 2 months for untreated patients and every 3 ± 1 months for treated patients. To determine SVR24, we analyzed the HCV RNA results collected at the closest time point occurring 24 weeks after the last dose of treatment, which we refer to as SVR24. According to the guideline of HCV infection by World Health Organizasion [ 16 ], the HCV RNA measurements were conducted at a central laboratory (the Peking University People’s Hospital) using the Abbott RealTime HCV assay from Abbott Laboratories in Des Plaines, IL, USA, with a lower limit of detection of 12 IU/ml, which was commercialized and had been widely applied.

EQ-5D

We evaluated the longitudinal HRQoL of patients every 12 months using an approved Chinese version of the EQ-5D-3 L. This measure has been tested for validity and reliability in populations across mainland China. The EQ-5D-3 L is a straightforward multidimensional assessment tool composed of two parts: the EQ-5D descriptive system and the EQ visual analogue scale (EQ-VAS). The EQ-5D-3 L descriptive system categorized patients’ health status into three levels of severity (no, moderate, or severe problems) across five dimensions (mobility [MO], self-care [SC], usual activities [UA], pain/discomfort [PD], and anxiety/depression [AD]), yielding scores that can be converted into a single EQ-5D utility for health status (with 1 representing full health and 0 representing death). We assigned the EQ-5D utility using a Chinese time trade-off value set (Chinese Time Trade-Off Values for EQ-5D Health States) [ 17 ].

Statistical analysis

We conducted a descriptive analysis of patients’ sociodemographic and clinical information, with categorical variables reported as percentages and continuous variables presented as mean ± standard deviation or median (interquartile range). We applied the Bonferroni correction to conduct multiple hypothesis testing to compare the proportion of patients experiencing moderate or severe problems in each domain of the EQ-5D, as well as the mean EQ-5D utility and EQ-VAS scores in patients with and without SVR24. According to the Bonferroni correction formula p ×(1/n), where p is the original threshold (0.05), and n is the total number of tests (n = 6), a p value of < 0.008 was considered statistically significant (Table S2 ).

To examine the associations between sociodemographic and clinical characteristics and changes in HRQoL over time, we applied generalized estimating equation (GEE) models. Sociodemographic and clinical variables were included into univariable analysis, and variables with significant statistical ( p < 0.05) and time point (baseline and every year up to 5 years) were included in the multivariate analysis. A p value of < 0.05 was considered statistically significant. We performed all analyses using SPSS 23.0 (SPSS Inc., Chicago, IL).

Results

Baseline sociodemographic and clinical status

The study enrolled 512 patients, but 18 dropped out during follow-up and 15 were excluded due to protocol violations. An additional 23 patients were excluded because they were unable to complete the intact HRQoL assessment, leaving 456 patients for the final analysis. During the follow-up period, joining other clinical studies related to Hepatitis C, loss to follow-up, withdrawal of informed consent, or missing certain visits can all lead to a reduction in the annual count of enrolled patients [ 14 ]. The sociodemographic characteristics of the patients are summarized in Table 1 , with a median age of 46.5 years (interquartile range: 36.5–57.0) and 57.5% males.

Table 1 Baseline sociodemographic characteristics of participants (n = 456) Parameter Gender Male 262 (57.5%) Female 193 (42.3%) Age, median (Q1, Q3), years 46.5(36.5, 57.0) 18–39 134 (29.4%) 40–59 233 (51.1%) ≥60 88 (19.3%) Residence East 101 (22.1%) West 99 (21.7%) South 87 (19.1%) North 85 (18.6%) Central 83 (18.2%) Marital status Single 56 (12.3%) Married 384 (84.2%) Separated/Divorced/Widowed 15 (3.3%) Occupation White collar 134 (29.4%) Blue collar 183 (40.1%) Unemployed 66 (14.5%) Other 72 (15.8%) Education Primary School 62 (13.6%) Junior school 117 (25.7%) High-school 125 (27.4%) College graduate 151 (33.1%) Monthly family income/per person a <2000 RMB 252 (55.3%) 2000–4999 RMB 163 (35.7%) ≥5000 RMB 39 (8.6%) a 1 RMB = 0.1457 USD.

Table 2 presents the clinical characteristics of patients included in the final analysis. Of these patients, 84.0% reported no discomfort symptoms, such as appetite decrease or nausea. Extrahepatic manifestations were reported by 9.7% of patients, and 9.6% had cirrhosis. Beck’s depression score of more than 17, indicating clinical depression, was observed in 9.7% of patients. The major HCV genotypes were genotype 1 (46.1%) and genotype 2 (25.4%). The baseline log10 HCV RNA was 6.10 (5.34, 6.55) IU/mL. Among the 335 patients (73.5%) who received antiviral therapy, 292 (64.0%) and 282 (61.8%) patients achieved SVR12 and SVR24, respectively, during the follow-up period. The median time between the actual detection of HCV RNA and the detection time of SVR24 is 65.5 (18.2, 57.0) days.

Table 2 Clinical characteristics of participants (n = 456) Parameter Route of HCV acquisition a Blood Transfusion 271 (59.4) Intravenous drug abuse 17 (3.7) Dental treatment 92 (21.1) Other 87 (19.1) Number of moderate or severe symptoms of discomfort, n (%) b 0 383 (84.0%) 1 56 (12.3%) ≥2 17 (3.7%) Extrahepatic manifestations, n (%) c Yes 45 (9.7%) No 411 (90.3%) Cirrhosis, n (%) Yes 44 (9.6%) No 412 (90.4%) Beck’s Depression Score, median (Q1, Q3) <17 411 (90.1%) ≥17 45 (9.7%) HCV Genotype 1 210 (46.1%) 2 116 (25.4%) Else 129 (28.3%) Log 10 HCV RNA, IU/mL, (Q1, Q3) 6.10 (5.34, 6.55) Duration of follow-up, median months, (Q1, Q3) 69.6 (69, 70) Antiviral therapy during follow-up, n (%) Yes 335 (73.5%) No 121 (26.5%) Achieving SVR 12 during follow-up, n (%) Yes 292 (64.0%) No 164 (36.0%) Achieving SVR 24 during follow-up, n (%) Yes 282 (61.8%) No 174 (38.2%) a Other route of HCV acquisition: sex, long-term exposure history to HCV patient, tattoo, piercings, intra-exam and treatment, and etc. Patients may report more than one route of HCV acquisition. b Uncomfortable symptoms: moderate or above malaise, appetite decrease, nausea, discomfort of right hypochondrium, fever, xanthochromia, xanthurenic and other uncomfortable symptoms. c Extrahepatic manifestation: Behcet’s disease, cryoglobulinemia, prediabetes, diabetes, hyperlipidemia, fatty liver, insulin resistance, fibromyalgia, membranoproliferative glomerulonephritis, membranous nephropathy, multiple myeloma, Raynaud’s syndrome, rheumatoid arthritis, Sjögren syndrome, systemic lupus erythematosus, thyroid dysfunction, skin lesions, hypertrophic cardiomyopathy, porphyria cutanea tarda, lichen planus, vasculitis, pulmonary fibrosis. SVR 12/24, Sustained virologic response 12/24 weeks post treatment

Health-related quality of life in HCV patients

Table S1 demonstrates the comparability of patients included in the study across sociodemographic and clinical factors each year (see Additional file 1 ). Table 3 indicates that at baseline, the EQ-5D utility and EQ-VAS were 0.916 ± 0.208 and 80.6 ± 13.0, respectively. Of the patients, 33 (7.2%) and 22 (4.8%) reported moderate or severe problems in the MO and UA domains, respectively, while 101 (22.1%) reported moderate or severe pain or discomfort in the PD domain and 98 (21.5%) reported moderate or severe anxiety or depression in the AD domain. Only 6 (1.3%) of patients reported difficulties in the SC domain.

Table 3 Quality of life of included participants Baseline (n = 456) 1st year (n = 335) 2nd year (n = 331) 3nd year (n = 302) 4th year (n = 253) 5th year (n = 209) Moderate Severe Moderate Severe Moderate Severe Moderate Severe Moderate Severe Moderate Severe EQ-5D MO, n (%) 31(6.8) 2(0.4) 19(5.7) 0(0) 17(5.1) 1(0.3) 17(5.6) 1(0.3) 17(6.7) 0(0) 16(7.7) 0(0) SC, n (%) 5(1.1) 1(0.2) 4(1.2) 0(0) 4(1.2) 0(0) 3(1.0) 0(0) 1(0.4) 0(0) 1(0.5) 0(0) UA, n (%) 19(4.2) 3(0.6) 18(5.4) 0(0) 14(4.2) 1(0.3) 11(3.6) 0(0) 13(5.1) 0(0) 11(5.3) 0(0) PD, n (%) 96(21.1) 5(1.1) 57(17.0) 3(0.9) 56(16.9) 3(0.9) 56(18.5) 1(0.3) 36(14.2) 1(0.4) 27(12.9) 1(0.5) AD, n (%) 96(21.1) 2(0.4) 42(12.5) 1(0.3) 38(11.5) 3(0.9) 31(10.3) 1(0.3) 23(9.1) 0(0) 18(8.6) 1(0.5) EQ-5D index, mean ± SD 0.916 ± 0.208 0.938 ± 0.177 0.936 ± 0.199 0.943 ± 0.153 0.956 ± 0.125 0.949 ± 0.159 EQ-5D VAS, mean ± SD 80.6 ± 13.0 82.1 ± 12.2 83.4 ± 12.7 85.9 ± 12.6 85.8 ± 13.1 86.9 ± 12.1 a Patients reported some problem (moderate or severe) in individual domain. MO, mobility difficulties; SC, self-care difficulties; UA, usual activities difficulties; PD, pain/discomfort; AD, anxiety/depression

The EQ-5D utility and EQ-VAS increased annually, and the proportion of patients reporting severe discomfort in any of the five dimensions of EQ-5D decreased gradually over time (Table 3 ). Starting from the first year, both the EQ-5D index and EQ-5D VAS scores of SVR group were significantly higher than those of the No SVR group. However, by the fifth year, this inter-group difference was no longer significant (Table S2 ).

Individual domain of EQ-5D stratified by SVR

Figure 1 illustrates the number of patients who reported moderate or severe problems in individual domains of EQ-5D during follow-up, stratified by SVR status. The numbers between patients with and without SVR became significant over time, particularly in the domains of MO and UA (5th year: MO, 8[4.8%] & 8[18.6%], p = 0.032; UA, 4 [2.4%] & 7 [16.3%], p = 0.021). Furthermore, a higher proportion of patients without SVR reported pain or discomfort compared to those with SVR (1st year: 21[12.2%] & 39[23.9%], p = 0.005; 2nd year: 20[9.9%] & 39 [20.2%], p = 0.000; 3rd year: 29[15.3%] & 28 [25.0%], p = 0.047; 4th year: 19[10.9%] & 18[22.8%], p = 0.027). Table S2 shows this in more detail (see Additional file 1 ).

Fig. 1 Health-related quality of life domain stratified by SVR or not over time. a Patients reported some problem (moderate or severe) in individual domain. MO, mobility difficulties; SC, self-care difficulties; UA, usual activities difficulties; PD, pain/discomfort; AD, anxiety/depression

Predictors of longitudinal EQ-5D utility and EQ-VAS score in HCV participants by GEE estimation

GEE estimation was used to explore predictors of longitudinal EQ-5D utility and EQ-VAS. As presented in Table 4 for univariable analysis. Gender, age, residence, marital status, education income, cirrhosis, beck’s depression score and duration of follow-up were found to be significantly associated with EQ-5D utility. Furthermore, achieving SVR24 was positively associated with EQ-5D utility ( β = 0.049, 95% CI [0.033, 0.065], p = 0.000). Gender, age, residence, marital status, education, income, cirrhosis, genotypes and duration of follow-up were significant predictors of EQ-VAS. Meanwhile, SVR24 was found to be a strong predictor of longitudinal EQ-VAS ( β = 5.933, 95% CI [4.827, 7.040], p = 0.000). As presented in Table 5 for multivariable analysis, age, income and SVR24 ( β = 0.040, 95% CI [0.023, 0.057], p = 0.000) were shown to be significant predictors of EQ-5D utility, while gender, age, genotypes and SVR24 ( β = 5.333, 95% CI [4.204, 6.462], p = 0.000) were associated with EQ-VAS over time.

Table 4 Predictors of longitudinal EQ-5D index and EQ-VAS score in HCV participants by univariable GEE estimation Parameter EQ-5D Index EQ-VAS Score β SE p value 95% CI β SE p value 95% CI Gender (Ref: Female) Male 0.025 0.012 0.033 0.002, 0.047 3.462 0.928 0.000 1.643, 5.281 Age (Ref: ≥ 60y) 18–39 0.074 0.016 0.000 0.042, 0.105 8.459 1.306 0.000 5.900, 11.019 40–59 0.029 0.017 0.082 -0.004, 0.062 3.166 1.280 0.013 0.658, 5.674 Residence (Ref: West) Central 0.037 0.018 0.036 0.002, 0.071 1.681 1.397 0.229 -1.058, 4.419 East 0.016 0.019 0.541 -0.025, 0.049 -1.379 1.371 0.314 -4.065, 1.308 North -0.019 0.022 0.378 -0.062, 0.024 -3.207 1.599 0.045 -6.342, -0.073 South 0.028 0.018 0.118 -0.007, 0.062 1.936 1.352 0.152 -0.714, 4.587 Marital status (Ref: Single) Separated / Divorced / Widowed -0.060 0.027 0.029 -0.113, -0.006 -10.961 2.412 0.000 -15.689, -6.233 Married -0.031 0.016 0.060 -0.063, 0.001 -4.372 1.208 0.000 -6.740, -2.004 Occupation (Ref: Unemployed) Blue collar -0.021 0.012 0.085 -0.046, 0.003 -1.306 1.398 0.350 -4.047, 1.435 White Collar -0.015 0.013 0.234 -0.039, 0.010 -0.781 1.469 0.595 -3.660, 2.099 Other -0.033 0.018 0.068 -0.068, 0.002 -1.709 1.825 0.349 -5.286, 1.868 Education (Ref: Primary School) Junior school 0.040 0.026 0.124 -0.011, 0.091 3.261 1.556 0.036 0.211, 6.311 High-school 0.026 0.026 0.316 -0.025, 0.077 3.255 1.586 0.040 0.147, 6.364 College graduate 0.050 0.025 0.047 0.001, 0.100 4.852 1.493 0.001 1.926, 7.778 Income (Ref: < 2000 RMB) 2000–4999 RMB -0.012 0.013 0.370 -0.037, 0.014 0.424 0.996 0.670 -1.529, 2.377 5000–7999 RMB 0.001 0.021 0.967 -0.041, 0.043 -0.805 2.086 0.700 -4.892, 3.283 8000–9999 RMB 0.064 0.007 0.000 0.049, 0.078 7.329 2.511 0.004 2.408, 12.251 ≥10,000 RMB 0.047 0.013 0.001 0.020, 0.074 3.951 3.046 0.195 -2.020, 9.921 Route of HCV acquisition Blood Transfusion -0.005 0.009 0.583 -0.022, 0.012 -0.314 0.558 0.574 -1.406, 0.779 Intravenous drug abuse 0.001 0.025 0.972 -0.048, 0.050 -1.936 1.333 0.147 -4.550, 0.678 Dental treatment 0.006 0.009 0.465 -0.011, 0.023 0.864 0.666 0.195 -0.442, 2.170 Other 0.003 0.011 0.813 -0.019, 0.025 0.603 0.642 0.347 -0.655, 1.861 Symptoms of discomfort (Ref: ≥ 2) 0 0.053 0.040 0.194 -0.027, 0.132 4.391 2.638 0.096 -0.779, 9.561 1 0.011 0.044 0.806 -0.076, 0.097 -1.517 2.974 0.610 -7.347, 4.312 Extrahepatic manifestation (Ref: No) -0.022 0.022 0.325 -0.066, 0.022 -2.470 1.755 0.159 -5.909, 0.970 Cirrhosis (Ref: No) -0.061 0.031 0.045 -0.122, -0.001 -5.741 1.640 0.000 -8.955, -2.526 Beck’s Depression Score (Ref: < 17) -0.043 0.017 0.013 -0.077, -0.009 -3.324 2.120 0.117 -7.479, 0.832 HCV Genotype (Ref: Else) 1 -0.028 0.016 0.073 -0.060, 0.003 -4.467 1.220 0.000 -6.857, -2.076 2 -0.016 0.013 0.225 -0.042, 0.010 -2.976 1.122 0.008 -5.175, − 0.777 Log10 HCV RNA, IU/mL 0.001 0.005 0.860 -0.009, 0.011 0.001 0.005 0.860 -0.009, 0.011 SVR24 (Ref: No) 0.049 0.008 0.000 0.033, 0.065 5.933 0.564 0.000 4.827, 7.040 Duration of follow-up, month -0.019 0.007 0.010 -0.033, -0.004 -1.521 0.531 0.004 -2.562, -0.480

Table 5 Predictors of longitudinal EQ-5D index and EQ-VAS score in HCV participants by multivariable GEE estimation Parameter EQ-5D Index EQ-VAS Score β SE p value 95% CI β SE p value 95% CI Gender (Ref: Female) Male 2.042 0.900 0.023 0.278, 3.806 Age (Ref: ≥ 60y) 18–39 0.048 0.016 0.003 0.016, 0.080 5.142 1.319 0.000 2.556, 7.727 40–59 0.015 0.017 0.400 -0.019, 0.049 1.388 1.209 0.251 -0.982, 3.758 Income (Ref: < 2000 RMB) 2000–4999 RMB 5000–7999 RMB 8000–9999 RMB 0.047 0.017 0.005 0.014, 0.080 ≥10,000 RMB 0.050 0.017 0.004 0.016, 0.084 HCV Genotype (Ref: Else) 1 -3.930 1.114 0.000 -6.114, -1.746 2 -1.537 1.034 0.137 -3.565, 0.490 SVR24 (Ref: No) 0.040 0.009 0.000 0.023, 0.057 5.333 0.576 0.000 4.204, 6.462

Discussion

In this prospective longitudinal multicenter study of Chinese patients with CHC, we found that the quality of life of patients in real world was impaired. Certain sociodemographic factors, such as gender, age, income as well as genotype, significantly influenced long-term changes in patients’ quality of life. Notably, HCV clearance had a significant impact on the long-term HRQoL of hepatitis C patients. This study shed light on the longitudinal changes in quality of life of real-world hepatitis C patients and provided a basis for the future medical care of these patients in China.

HCV has been widely reported to have a profound negative impact on HRQoL, work productivity and other PROs [ 18 , 19 ]. A meta-analysis of 51 clinical studies and 15,053 patients suggested that CHC was associated with a significant impairment in global health status, and the impairment was greater in advanced disease [ 20 ]. Sociodemographic and clinical characteristics were found to be associated with HRQoL of HCV patients. For instance, occupation, comorbidities, overweight, and feeling worried about CHC progression affected EQ-5D utility and EQ-VAS scores [ 21 ]. In our previous study of 997 Chinese HCV patients, we found significant negative associations between HRQoL and sociodemographic and clinical factors such as moderate or severe symptoms of discomfort, disease profile, and depression [ 8 ]. In our real-world study of HCV patients, sociodemographic characteristics including gender, age and income were shown to be significant predictors of HRQoL. Previous studies have indicated disparities in HRQoL of HCV patients in different settings. For example, compared with patients recruited from hospitals, patients recruited from the community setting had lower health utilities [ 22 ]. Besides, compared with clinical trial enrollees, patients in real-world practices were less commonly enrolled from high-income population, older, more commonly female, less employed, had more type 2 diabetes, anxiety and clinically overt fatigue but less cirrhosis. Sociodemographic confounders were the main reason of differences in HRQoL of HCV patients in different setting [ 7 ]. In longitudinal studies of DAAs treatment, utilities have also been shown to improve after treatment in patients with CHC in various settings. However, community-based patients may still face challenges related to comorbid health and social conditions that are not meaningfully addressed by treatment [ 9 ]. The HRQoL of 1,180 participants in a real-world setting from the German Hepatitis C Registry also suggested that roughly half of the patients failed to achieve a clinically important improvement after DAAs therapy [ 23 ]. Besides, health conditions and lifestyle also contributed to HRQoL of HCV Patients a lot. For example, community-based patients may face challenges related to comorbid health and social conditions that are not meaningfully addressed by treatment [ 9 ]. Treating mental illness by psychoeducation may also contribute to the improved PRO of HCV patients [ 24 ]. Another example of the impact of setting on the HRQoL of HCV patients who received DAAs was in people who injected drugs (PWID). HRQoL in PWID patients improved following treatment for HCV infection with elbasvir/grazoprevir, suggesting that eradication of HCV infection with DAAs was associated with improved HRQoL [ 25 ]. However, a study on PWID in community settings suggested that DAAs treatment was not associated with longitudinal change in PROs scores [ 26 ]. The above content indicated that differences in the quality of life of HCV patients in different environments may be due to sociodemographic factors. The results from clinical trials and clinical studies may not fully explain the factors influencing the quality of life of HCV patients in the real world and the impact of DAA treatment on their quality of life. Therefore, our study provided new insights into this issue in the real world.

It has been reported that HCV clearance improved HRQL and other PROs in HCV patients, regardless of the stage of liver disease. Patients with HCV-related decompensated cirrhosis who were given DAAs showed a clinically significant early and sustained improvement in PROs [ 27 – 30 ]. Marked improvements involving physical, mental, and hepatitis-specific indices in HRQoL of HCV patients with cirrhosis were reported between baseline and SVR12 timepoints. Another study of 1,564 patients, of whom 47% had cirrhosis, suggested that mean PROs scores improved slightly in the overall cohort, and age, baseline mental health issues, and a higher number of health comorbidities were predictors of PROs improvements [ 31 ]. Sofosbuvir-based DAAs therapy was associated with a significant improvement in PROs 6 months after treatment end in patients with CHC [ 32 ]. However, long-term effects on patient HRQoL after HCV clearance are still lacking. A study assessing the impact of DAAs-mediated HCV clearance on HRQoL from DAAs initiation to 1 year after confirmed SVR24 found that the average SF-8 scores were higher than the Japanese national standard values for bodily pain (BP) and mental health at baseline and for general health at 1-year post-SVR24 [ 33 ]. Another real-world study of 1601 HCV patients indicated that the improvements in PROs reported by HCV patients who achieved SVR following DAAs therapy were durable at 12 months post-treatment [ 12 ]. The longest period of follow-up in similar studies was nearly 3 years, during which DAAs therapy improved HRQoL significantly in the long term, and the improvement did not correlate with the severity of liver fibrosis [ 34 , 35 ]. However, another long-term assessment found that although patients with decompensated cirrhosis experienced improvement of HRQoL after DAAs therapy, there was a decline after 2 years [ 36 ]. Based on the above research results, we need to conduct longer-term studies to evaluate the long-term impact of SVR on the quality of life of HCV patients in the real world. To our knowledge, our study is currently the longest real-world follow-up study evaluating the impact of SVR on HRQoL in HCV patients. From our research results, HCV patients will experience long-lasting improvements in their quality of life after achieving SVR.

We observed a significant improvement in the anxiety/depression domain following HCV clearance in our study. Previous research also indicated that HCV eradication led to a decrease in anxiety prevalence from 30.4 to 19.1% and depression from 35.2–18.2% [ 37 , 38 ]. Furthermore, patients with severe mental illness and hepatitis C virus infection can benefit from DAAs treatment [ 39 ]. However, in our study, 18 (10.8%) and 12 (7.2%) patients with SVR still reported problems in the pain/discomfort and anxiety/depression domains, respectively. This issue has also been reported in other studies. A meta-analysis revealed that all items of the SF-36 questionnaire improved significantly (p < 0.05) from the pretreatment to post-treatment period, except for bodily pain and role limitations-emotional [ 10 ]. Additionally, a real-world study found that mental health remained a concern even after treatment with currently used DAAs medications [ 40 ]. We found that starting from the first year, both the EQ-5D index and EQ-5D VAS scores of SVR group were significantly higher than those of the No SVR group. However, by the fifth year, this inter-group difference was no longer significant. This suggests that the impact of SVR on HRQoL of HCV patients may have a time-limited effect, only influencing the first few years after achieving SVR. Whether this effect has a long-term impact remains inconclusive.

The treatment approach itself may also affect the quality of life of CHC patients. It appeared that DAAs therapy did not have a negative impact on, but instead improved, the overall quality of life and psychological state of adult patients with CHC [ 40 , 41 ]. However, the addition of ribavirin to antiviral regimens can compromise HRQoL indices during antiviral therapy [ 42 ]. Patients receiving interferon-based treatment had lower utilities compared to those on interferon-free treatment [ 20 ]. Due to the fact that DAAs were only introduced to the Chinese market at the end of 2017, and the formulation and initiation of this research project occurred prior to that, with participation in HCV-related clinical trials and studies being considered as exclusion criteria in the research design. One limitation of our study was that all patients in our study received interferon-containing regimens, which may have underestimated the improvement in quality of life resulting from virus clearance to some extent. Another limitation of this study is that it is an observational study in the real world, without any intervention for HCV patients’ treatment, with a follow-up time of once every six months. The time when the virus was undetectable at the time closest to SVR24 was selected as the time of SVR, so it was not possible to obtain the quality of life at the time of SVR with absolute accuracy. As the timing of HCV RNA testing after cessation of therapy is typically later than SVR24, categorizing patients into SVR24 and No SVR24 groups based on this does not affect the accuracy of grouping. Although, EQ-5D-5 L has been demonstrated to have higher sensitivity, as this is a nationwide, multicenter real-world study with a large sample size, extensive data collection, and a long follow-up period, in order to enhance patient compliance and improve the feasibility of comprehensive data collection, we opted for the relatively simple EQ-5D-3 L instrument. Besides, for the purpose of a more intuitive presentation of the research results, we employed t-tests and chi-squared tests when analyzing the individual domains of EQ-5D stratified by SVR at each time point. However, as a study involving repeated measurements and replicated data, these analytical methods did not account for the elimination of confounding factors. While we addressed the influence of confounding factors such as time through the subsequent Generalized Estimating Equation (GEE) analysis. However, when interpreting the results of this study, it’s important to consider the aforementioned limitations of our research.

Conclusions

This prospective national study in China indicated that virus clearance improved the long-term HRQoL in patients with CHC in the first few years. Certain sociodemographic factors, such as gender, age, income as well as genotype, significantly influenced long-term changes in patients’ quality of life.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Acknowledgements

We would like to acknowledge Hong Li (currently at Bristol-Myers Squibb, China and previously at Global Health Economics and Outcomes Research Department, Bristol-Myers Squibb, Lawrenceville, NJ, USA at the time the study was conducted) for his contribution to the study design and CCgenos study investigators for their contributions to the study data acquisition, and the patients and their families for their support and dedication.

Author contributions

LW and HR designed the work and reviewed the article. RH interpreted the data and drafted the manuscript. RH, JS, HC, JL and QX collected the data. JF interpreted the data. All authors read and approved the final manuscript.

Funding

Project supported by Bristol-Myers Squibb (LW, AI452-018ST), Peking University People’s Hospital Scientific Research Development Funds (RH, RDJ2022-21) and Peking University Hepatology Institute Qi-Min Project (RH).

Data Availability

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study protocols were approved by a central review board (the ethics committee of Peking University People’ s Hospital), the institutional review boards of each participating center, and the China National Human Genetic Resource Management Office (2010). All methods were carried out in accordance with relevant guidelines and regulations. Informed consent was obtained from all subjects and/or their legal guardian(s).

Consent for publication

Not applicable.

Competing interests

LW has received research grants from Abbvie, Bristol-Myers Squibb, and Gilead, and consulting for Gilead, Huahui, MSD, Pfizer, speaker for Ascletis Pharma, Bristol- Myers Squibb, Gilead, and Kaiyin. HR has received a speaker honorarium from Bristol-MyersSquibb, Gilead, and AbbVie. Other authors declare that they have no competing interests.

Abbreviations

Hepatitis C virus

Hepatocellular carcinoma

Direct-acting antivirals

Sustained virologic response

Patient-reported outcomes

Chronic hepatitis C

Health-related quality of life

People who injected drugs

References

1. Cui F Blach S Manzengo Mingiedi C Gonzalez MA Sabry Alaama A Mozalevskis A Global reporting of progress towards elimination of Hepatitis B and Hepatitis C Lancet Gastroenterol Hepatol 2023 8 332 42 10.1016/S2468-1253(22)00386-7 36764320

2. WHO, Global hepatitis report. 2017. https://apps.who.int/iris/bit , 2020.

3. Ghany MG Morgan TR Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and treating Hepatitis C virus Infection Hepatology 2020 71 686 721 10.1002/hep.31060 31816111 PMC9710295

4. EASL recommendations on treatment of hepatitis C Final update of the series(☆) J Hepatol 2020 73 1170 218 32956768 10.1016/j.jhep.2020.08.018

5. Liu YB Chen MK Epidemiology of liver Cirrhosis and associated Complications: current knowledge and future directions World J Gastroenterol 2022 28 5910 30 10.3748/wjg.v28.i41.5910 36405106 PMC9669831

6. Veracruz N Gish RG Cheung R Chitnis AS Wong RJ Global trends and the impact of chronic Hepatitis B and C on disability-adjusted life years Liver Int 2022 42 2145 53 10.1111/liv.15347 35753064

7. Younossi ZM Yu ML El-Kassas M Esmat G Castellanos Fernández MI Buti M Severe impairment of patient-reported outcomes in patients with chronic Hepatitis C virus Infection seen in real-world practices across the world: data from the global liver registry J Viral Hepat 2022 29 1015 25 10.1111/jvh.13741 36036096

8. Huang R Rao H Shang J Chen H Li J Xie Q A cross-sectional assessment of health-related quality of life in Chinese patients with chronic Hepatitis C virus Infection with EQ-5D Health Qual Life Outcomes 2018 16 124 10.1186/s12955-018-0941-8 29903024 PMC6003185

9. Wong WWL, Wong J, Bremner KE, Saeed Y, Mason K, Phoon A et al. Impact of direct-acting antiviral treatment on health utility in patients with chronic Hepatitis C in hospital and community settings. Liver Int. 2023. 10.1111/liv.15518 36606706

10. He N Feng G Hao S Xu M Liu J Kong F The impact of direct-acting antivirals on quality of life in patients with Hepatitis C virus Infection: a meta-analysis Ann Hepatol 2022 27 100705 10.1016/j.aohep.2022.100705 35398571

11. Sung JC Bosh C Wyatt B Miller M Harty A Del Bello D Hepatitis C cure improved patient-reported outcomes in patients with and without liver fibrosis in a prospective study at a large urban medical center J Viral Hepat 2020 27 350 59 10.1111/jvh.13234 31742821

12. Serper M Evon DM Amador J Stewart PW Sarkar S Lok AS Patient-reported outcomes 12 months after Hepatitis C treatment with direct-acting antivirals: results from the PROP UP study Liver Int 2021 41 692 704 10.1111/liv.14781 33387381 PMC7969418

13. Rao HY Li H Chen H Shang J Xie Q Gao ZL Real-world treatment patterns and clinical outcomes of HCV treatment-naive patients in China: an interim analysis from the CCgenos study J Gastroenterol Hepatol 2017 32 244 52 10.1111/jgh.13467 27289083

14. Rao H Xie Q Shang J Gao Z Chen H Sun Y Real-world clinical outcomes among individuals with chronic HCV Infection in China: CCgenos study Antivir Ther 2019 24 473 83 10.3851/IMP3334 31566575

15. Songtanin B, Nugent K. Burden, Outcome, and comorbidities of Extrahepatic manifestations in Hepatitis C virus Infection. Biology (Basel). 2022; 12. 10.3390/biology12010023 PMC9855523 36671716

16. Abraham GM Obley AJ Humphrey LL Qaseem A Centor RM Akl E World Health Organization Guidelines on treatment of Hepatitis C virus Infection: best practice advice from the American College of Physicians Ann Intern Med 2021 174 98 100 10.7326/M19-3860 33017566

17. Liu GG Wu H Li M Gao C Luo N Chinese time trade-off values for EQ-5D health states Value Health 2014 17 597 604 10.1016/j.jval.2014.05.007 25128053

18. Cheng Q, Cunningham EB, Shih S, Amin J, Bruneau J, Artenie AA et al. Patient-reported outcomes during and after Hepatitis C Virus Direct-acting antiviral treatment among people who inject Drugs. Value Health. 2023. 10.1016/j.jval.2022.12.016 36646278

19. de Ledinghen V Hanslik B Moussalli J Si Ahmed SN Ouzan D Larrey D Hepatitis C virus Infection impacts work productivity and fatigue: an epidemiologic real-life study Ann Hepatol 2019 18 708 14 10.1016/j.aohep.2019.04.015 31164266

20. Saeed YA Phoon A Bielecki JM Mitsakakis N Bremner KE Abrahamyan L A systematic review and Meta-analysis of Health utilities in patients with chronic Hepatitis C Value Health 2020 23 127 37 10.1016/j.jval.2019.07.005 31952667

21. Cossais S Schwarzinger M Pol S Fontaine H Larrey D Pageaux GP Quality of life in patients with chronic Hepatitis C Infection: severe comorbidities and Disease perception matter more than Liver-Disease stage PLoS ONE 2019 14 e0215596 10.1371/journal.pone.0215596 31050687 PMC6499434

22. Saeed YA Mason K Mitsakakis N Feld JJ Bremner KE Phoon A Disparities in health utilities among Hepatitis C patients receiving care in different settings Can Liver J 2023 6 24 38 10.3138/canlivj-2022-0009 36908577 PMC9997513

23. Ohlendorf V Schäfer A Christensen S Heyne R Naumann U Link R Only partial improvement in health-related quality of life after treatment of chronic Hepatitis C virus Infection with direct acting antivirals in a real-world setting-results from the German Hepatitis C-Registry (DHC-R) J Viral Hepat 2021 28 1206 18 10.1111/jvh.13546 34003549

24. North CS Pollio DE Sims OT Jain MK Brown GR Downs DL An effectiveness study of group psychoeducation for Hepatitis C patients in community clinics Eur J Gastroenterol Hepatol 2017 29 679 85 10.1097/MEG.0000000000000860 28195874 PMC5404973

25. O’Sullivan M Jones AM Gage H Jordan J MacPepple E Williams H ITTREAT (Integrated Community Test - Stage - TREAT) Hepatitis C service for people who use Drugs: real-world outcomes Liver Int 2020 40 1021 31 10.1111/liv.14403 32048798

26. Goutzamanis S Spelman T Harney B Dietze P Stoove M Higgs P Patient-reported outcomes of the treatment and Prevention Study: a real-world community-based trial of direct-acting antivirals for Hepatitis C among people who inject Drugs J Viral Hepat 2021 28 1068 77 10.1111/jvh.13516 33880820

27. Younossi ZM Stepanova M Afdhal N Kowdley KV Zeuzem S Henry L Improvement of health-related quality of life and work productivity in chronic Hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir J Hepatol 2015 63 337 45 10.1016/j.jhep.2015.03.014 25795586

28. Ali B Raja IUH Choudhry A Nawaz AA Successful eradication of Hepatitis-C virus with Sofosbuvir based antiviral treatment results in improvement in quality of life in cirrhotic patients Pak J Med Sci 2022 38 822 25 10.12669/pjms.38.4.4537 35634624 PMC9121959

29. McPhail SM Amarasena S Stuart KA Hayward K Gupta R Brain D Assessment of health-related quality of life and health utilities in Australian patients with Cirrhosis JGH Open 2021 5 133 42 10.1002/jgh3.12462 33490623 PMC7812472

30. Younossi ZM Stepanova M Charlton M Curry MP O’Leary JG Brown RS Patient-reported outcomes with sofosbuvir and velpatasvir with or without Ribavirin for Hepatitis C virus-related decompensated Cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial Lancet Gastroenterol Hepatol 2016 1 122 32 10.1016/S2468-1253(16)30009-7 28404069

31. Evon DM Sarkar S Amador J Lok AS Sterling RK Stewart PW Patient-reported symptoms during and after direct-acting antiviral therapies for chronic Hepatitis C: the PROP UP study J Hepatol 2019 71 486 97 10.1016/j.jhep.2019.04.016 31096006 PMC6959970

32. Marcellin F Mourad A Lemoine M Kouanfack C Seydi M Carrieri P Patient-reported outcomes with direct-acting antiviral treatment for Hepatitis C in West and Central Africa (TAC ANRS 12311 trial) JHEP Rep 2023 5 100665 10.1016/j.jhepr.2022.100665 36686592 PMC9853347

33. Miyasaka A Yoshida Y Suzuki A Takikawa Y Health-related quality of life in patients with chronic Hepatitis C treated with sofosbuvir-based treatment at 1-year post-sustained virological response Qual Life Res 2021 30 3501 09 10.1007/s11136-021-02874-6 34013404 PMC8602143

34. Goñi Esarte S Juanbeltz R Martínez-Baz I Castilla J San Miguel R Herrero JI Long-term changes on health-related quality of life in patients with chronic Hepatitis C after viral clearance with direct-acting antiviral agents Rev Esp Enferm Dig 2019 111 445 52 10.17235/reed.2019.6063/2018 31066286

35. Ichikawa T Miyaaki H Miuma S Motoyoshi Y Yamashima M Yamamichi S Direct-acting antivirals improved the quality of life, ameliorated Disease-related symptoms, and augmented muscle volume three years later in patients with Hepatitis C Virus Intern Med 2020 59 2653 60 10.2169/internalmedicine.5102-20 33132304 PMC7691030

36. Younossi ZM Racila A Muir A Bourliere M Mangia A Esteban R Long-term patient-centered outcomes in cirrhotic patients with chronic Hepatitis C after achieving sustained Virologic Response Clin Gastroenterol Hepatol 2022 20 438 46 10.1016/j.cgh.2021.01.026 33493697

37. Slonka J, Piotrowski D, Janczewska E, Pisula A, Musialik J, Jaroszewicz J. Significant decrease in the prevalence of anxiety and depression after Hepatitis C eradication. J Clin Med. 2022; 11. 10.3390/jcm11113044 PMC9181745 35683432

38. Kaur H Dhiman RK Kulkarni AV Premkumar M Singh V Duseja AK Improvement of chronic HCV infection-related depression, anxiety, and neurocognitive performance in persons achieving SVR-12: a real-world cohort study J Viral Hepat 2022 29 395 406 10.1111/jvh.13668 35266624

39. Gutiérrez-Rojas L, de la Gándara Martín JJ, García Buey L, Uriz Otano JI, Mena Á, Roncero C. Patients with severe mental Illness and Hepatitis C virus Infection benefit from new pangenotypic direct-acting antivirals: results of a literature review. Gastroenterol Hepatol. 2022. 10.1016/j.gastrohep.2022.06.001 35718017

40. Krüger K, Rossol S, Krauth C, Buggisch P, Mauss S, Stoehr A et al. Real-world experience for the outcomes and costs of treating Hepatitis C patients: results from the German Hepatitis C-Registry (DHC-R). Z Gastroenterol. 2022. 10.1055/a-1852-5713 PMC10162862 35839795

41. Bertino G Ragusa R Corsaro LS Frazzetto E Messina V Inguscio L Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2) Health Psychol Res 2020 8 9450 33553794 10.4081/hpr.2020.9450 PMC7859961

42. Fagundes RN Ferreira L Pace FHL Health-related quality of life and fatigue in patients with chronic Hepatitis C with therapy with direct-acting antivirals agents interferon-free PLoS ONE 2020 15 e0237005 10.1371/journal.pone.0237005 32813740 PMC7437906